\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ significant\\ for\\ mild\\,\\ non\\-tender\\ cervical\\ lymphadenopathy\ \(0\)\
\-\ laboratory\\ unremarkable\ \(0\)\
\-\ patient\\ was\\ recently\\ diagnosed\\ and\\ is\\ undergoing\\ radiation\\ therapy\\ at\\ this\\ time\\.\ \(0\)\
\-\ \\â\\€\\¢\\ cxr\\:\\ enlargement\\ of\\ the\\ right\\ paratracheal\\ stripe\\ \\(8mm\\)\\.\ \(0\)\
\-\ \\â\\€\\¢\\ ct\\,\\ neck\\:\\ \\ 2\\.4\\ x\\ 2\\.4\\ cm\\ mediastinal\\ mass\\ \\(enlarged\\ lymph\\ node\\)\ \(0\)\
\-\ classic\\ nodular\\ sclerosing\\ hodgkin\\â\\€\\™s\\ lymphoma\\ \\(stage\\ ii\\)\ \(0\)\
\-\ \\â\\€\\¢\\ malignancy\ \(1\)\
\-\ \\Â\\»\\ hodgkin\\â\\€\\™s\\ disease\ \(0\)\
\-\ \\Â\\»\\ non\\-hodgkin\\â\\€\\™s\\ lymphoma\ \(0\)\
\-\ \\Â\\»\\ mediastinal\\ malignancy\ \(0\)\
\-\ \\â\\€\\¢\\ benign\\ neoplasm\ \(1\)\
\-\ \\â\\€\\¢\\ granulomatous\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ other\\ inflammation\\ \\(abscess\\)\ \(0\)\
\-\ \\â\\€\\¢\\ congenital\\ abnormality\ \(0\)\
\-\ 27\\ yr\\ old\\ woman\\ with\\ c\\/o\\ lymphadenopathy\\ and\\ fatigue\\ for\\ several\\ months\ \(1\)\
\-\ the\\ right\\ paratracheal\\ stripe\\ is\\ usually\\ 2mm\\ wide\\,\\ but\\ may\\ be\\ up\\ to\\ 5mm\\ wide\\.\\ \\ an\\ enlarged\\ paratracheal\\ stripe\\ \\(\\>5mm\\)\\ is\\ an\\ important\\ marker\\ for\\ otherwise\\ subtle\\ adenopathy\\,\\ as\\ well\\ as\\ tracheal\\ tumor\\,\\ mediastinal\\ inflammation\\ or\\ hemorrhage\\,\\ pleural\\ thickening\\ or\\ pleural\\ effusion\\.\\ \\ the\\ margins\\ of\\ the\\ paratracheal\\ stripe\\ are\\:\\ \ \(0\)\
\-\ 1\\.\\ distal\\ end\\â\\€\\”formed\\ by\\ the\\ azygous\\ vein\ \(1\)\
\-\ 2\\.\\ medial\\ margin\\â\\€\\”the\\ air\\-soft\\ tissue\\ interface\\ along\\ the\\ right\\ mucosal\\ surface\\ of\\ the\\ trachea\ \(1\)\
\-\ 3\\.\\ outer\\ margin\\â\\€\\”begins\\ around\\ the\\ medial\\ end\\ of\\ the\\ clavicle\\ and\\ is\\ formed\\ by\\ the\\ rul\\ plural\\ surface\ \(0\)\
\-\ the\\ stripe\\ ends\\ where\\ the\\ rul\\ bronchus\\ goes\\ under\\ the\\ azygous\\ vein\\ as\\ it\\ arches\\ anteriorly\\ to\\ empty\\ into\\ the\\ svc\\.\ \(0\)\
\-\ the\\ malignant\\ lymphomas\\ are\\ divided\\ into\\ hodgkin\\â\\€\\™s\\ and\\ non\\-hodgkin\\â\\€\\™s\\ groups\\.\\ \\ sir\\ thomas\\ hodgkin\\ was\\ the\\ first\\ to\\ describe\\ hodgkin\\â\\€\\™s\\ disease\\ in\\ 1932\\.\\ \\ hodgkin\\â\\€\\™s\\ can\\ present\\ at\\ any\\ age\\,\\ but\\ it\\ is\\ more\\ prevalent\\ among\\ adolescents\\ and\\ young\\ adults\\.\\ \\ it\\ typically\\ presents\\ as\\ painless\\,\\ rubbery\\ lymphadenopathy\\ involving\\ the\\ superficial\\ lymph\\ node\\ groups\\.\\ \\ cervical\\ nodes\\ are\\ involved\\ nearly\\ 70\\%\\ of\\ the\\ time\\.\\ \\ approximately\\ half\\ of\\ patients\\ also\\ have\\ splenomegaly\\.\\ \\ mediastinal\\ involvement\\ occurs\\ in\\ approximately\\ 10\\%\\ of\\ patients\\,\\ and\\ mediastinal\\ involvement\\ is\\ characteristic\\ of\\ the\\ nodular\\ sclerosing\\ type\\ \\(as\\ in\\ this\\ patient\\)\\.\\ \\ cutaneous\\ involvement\\ can\\ occur\\ and\\ is\\ usually\\ a\\ late\\ complication\\.\\ \\ patients\\ may\\ also\\ present\\ with\\ constitutional\\ symptoms\\ \\(night\\ sweats\\,\\ pruritis\\,\\ fatigue\\,\\ weight\\ loss\\,\\ etc\\)\\ with\\ widespread\\ disease\\.\\ \\ \ \(0\)\
\-\ the\\ diagnosis\\ of\\ hodgkin\\â\\€\\™s\\ disease\\ is\\ made\\ by\\ lymph\\ node\\ biopsy\\ \\(as\\ was\\ done\\ in\\ this\\ patient\\)\\.\\ \\ there\\ are\\ 4\\ histological\\ types\\:\ \(0\)\
\-\ 1\\.\\	nodular\\ sclerosing\\ \\(\\>50\\%\\,\\ most\\ common\\;\\ worst\\ prognosis\\)\ \(0\)\
\-\ 2\\.\\	mixed\\ cellularity\\ \\(25\\%\\)\ \(0\)\
\-\ 3\\.\\	lymphocyte\\ predominant\\ \\(5\\%\\;\\ best\\ prognosis\\)\ \(0\)\
\-\ 4\\.\\	lymphocyte\\ depleted\\ \\(5\\%\\)\ \(0\)\
\-\ staging\\ of\\ hodgkin\\â\\€\\™s\\ disease\\ is\\ made\\ by\\ the\\ use\\ of\\ cxr\\,\\ bm\\ biopsy\\,\\ and\\ ct\\ imaging\\.\\ \\ there\\ are\\ 4\\ stages\\:\ \(0\)\
\-\ 1\\.\\	stage\\ i\\â\\€\\”confined\\ to\\ one\\ lymph\\ node\\ group\\ \\(90\\%\\ 5\\-yr\\ survival\\ rate\\)\ \(0\)\
\-\ 2\\.\\	stage\\ ii\\â\\€\\”confined\\ to\\ 2\\ or\\ more\\ lymph\\ node\\ groups\\ on\\ one\\ side\\ of\\ the\\ diaphragm\ \(0\)\
\-\ 3\\.\\	stage\\ iii\\â\\€\\”involving\\ nodes\\ on\\ both\\ sides\\ of\\ the\\ diaphragm\ \(0\)\
\-\ 4\\.\\	stage\\ iv\\â\\€\\”extra\\-nodal\\ disease\\ \\(60\\%\\ 5\\-yr\\ survival\\ rate\\)\\ \ \(0\)\
\-\ treatment\\ involves\\ radiation\\ therapy\\ and\\/or\\ chemotherapy\\.\\ \\ patients\\ with\\ stage\\ i\\ or\\ stage\\ ii\\ hodgkin\\â\\€\\™s\\ disease\\ are\\ usually\\ treated\\ by\\ radiation\\ therapy\\,\\ while\\ stage\\ iii\\ \\&\\ iv\\ disease\\ is\\ usually\\ treated\\ with\\ radiation\\ therapy\\ and\\ chemotherapy\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ mendenhall\\,\\ np\\.\\ \\â\\€\\œthe\\ role\\ of\\ radiation\\ in\\ the\\ management\\ of\\ hodgkin\\â\\€\\™s\\ disease\\:\\ an\\ update\\,\\â\\€\\\\ cancer\\ invest\\ 1999\\;\\ 17\\:47\\-55\\.\ \(0\)\
\-\ 2\\.\\ potter\\,\\ r\\.\\ \\â\\€\\œpediatric\\ hodgkin\\â\\€\\™s\\ disease\\,\\â\\€\\\\ eur\\ j\\ cancer\\ 1999\\;\\ 35\\:\\ 1466\\-1477\\.\ \(0\)\
\-\ 3\\.\\ wirth\\,\\ a\\,\\ et\\ al\\,\\ \\â\\€\\œcurrent\\ trends\\ in\\ the\\ management\\ of\\ early\\ stage\\ hodgkin\\â\\€\\™s\\ disease\\,\\â\\€\\\\ aust\\ nz\\ j\\ med\\ 1999\\;\\ 29\\:\\ 535\\-544\ \(0\)\
\-\ 4\\.\\ http\\:\\/\\/www\\.surgical\\-tutor\\-org\\/tutorials\\/hodgkins\\.htm\ \(1\)\
\-\ 5\\.\\ http\\:\\/\\/rad\\.usuhs\\.mil\\/rad\\/chest\\_review\\/mediasti\\/mediasti\\.html\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hodgkin\\:\\ 0\\.09865244258114406\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.05131738425871859\ \(0\)\
\-\ stage\\:\\ 0\\.05070372466824593\ \(0\)\
\-\ s\\:\\ 0\\.04924262700539356\ \(0\)\
\-\ stripe\\:\\ 0\\.04325071560354171\ \(0\)\
\-\ paratracheal\\:\\ 0\\.03307438962081466\ \(0\)\
\-\ node\\:\\ 0\\.030218266194189092\ \(0\)\
\-\ mediastinal\\:\\ 0\\.02803811915089446\ \(0\)\
\-\ 5\\-yr\\:\\ 0\\.027250443350746518\ \(0\)\
\-\ lymph\\:\\ 0\\.02665797843079325\ \(0\)\
\-\ disease\\:\\ 0\\.0259054876268755\ \(0\)\
\-\ groups\\:\\ 0\\.025424948595631963\ \(0\)\
\-\ \\%\\:\\ 0\\.024646937042918177\ \(0\)\
\-\ sclerosing\\:\\ 0\\.023435788137277907\ \(0\)\
\-\ 1999\\:\\ 0\\.02246627439141133\ \(0\)\
\-\ radiation\\:\\ 0\\.02167118430882795\ \(0\)\
\-\ lymphocyte\\:\\ 0\\.020458404471809206\ \(0\)\
\-\ \\Â\\»\\:\\ 0\\.019522480237921514\ \(0\)\
\-\ \\:\\:\\ 0\\.01921641881900667\ \(0\)\
\-\ rul\\:\\ 0\\.018679844518475167\ \(0\)\
\-\ 3\\.\\:\\ 0\\.01807650208433216\ \(0\)\
\-\ azygous\\:\\ 0\\.01769544349492483\ \(0\)\
\-\ non\\-hodgkin\\:\\ 0\\.017558034646174184\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.016953787420666482\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.01684884794594009\ \(0\)\
\-\ 2\\.\\:\\ 0\\.016800272901392632\ \(0\)\
\-\ 5mm\\:\\ 0\\.016635336072585324\ \(0\)\
\-\ nodular\\:\\ 0\\.01662013820917424\ \(0\)\
\-\ 1\\.\\:\\ 0\\.01650194229550294\ \(0\)\
\-\ 2\\.4\\:\\ 0\\.01644207376352401\ \(0\)\
\-\ usually\\:\\ 0\\.01604283309963993\ \(0\)\
\-\ \\;\\:\\ 0\\.015652404856666104\ \(0\)\
\-\ \\(\\:\\ 0\\.015630701958908883\ \(0\)\
\-\ 4\\.\\:\\ 0\\.01560037080556784\ \(0\)\
\-\ \\)\\:\\ 0\\.015439764589777853\ \(0\)\
\-\ \\â\\€\\œ\\:\\ 0\\.014798304100985284\ \(0\)\
\-\ \\â\\€\\\\:\\ 0\\.014715354032589108\ \(0\)\
\-\ involvement\\:\\ 0\\.014522126692246444\ \(0\)\
\-\ diaphragm\\:\\ 0\\.01420714287106767\ \(0\)\
\-\ wide\\:\\ 0\\.01416201520670553\ \(0\)\
\-\ survival\\:\\ 0\\.01416201520670553\ \(0\)\
\-\ therapy\\:\\ 0\\.014124518060220173\ \(0\)\
\-\ fatigue\\:\\ 0\\.01411753688382423\ \(0\)\
\-\ patients\\:\\ 0\\.013672795050176358\ \(0\)\
\-\ end\\â\\€\\”formed\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ margin\\â\\€\\”the\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ margin\\â\\€\\”begins\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ 1932\\.\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ i\\â\\€\\”confined\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ ii\\â\\€\\”confined\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ iii\\â\\€\\”involving\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ iv\\â\\€\\”extra\\-nodal\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ mendenhall\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ 17\\:47\\-55\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ 1466\\-1477\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ wirth\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ trends\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ aust\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ nz\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ 535\\-544\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ \\/\\/www\\.surgical\\-tutor\\-org\\/tutorials\\/hodgkins\\.htm\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ \\/\\/rad\\.usuhs\\.mil\\/rad\\/chest\\_review\\/mediasti\\/mediasti\\.html\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ air\\-soft\\:\\ 0\\.01255389682133934\ \(0\)\
\-\ invest\\:\\ 0\\.01255389682133934\ \(0\)\
\-\ prognosis\\:\\ 0\\.012529658390011567\ \(0\)\
\-\ as\\:\\ 0\\.0119868084008729\ \(0\)\
\-\ nodes\\:\\ 0\\.01193103977238095\ \(0\)\
\-\ j\\:\\ 0\\.01193103977238095\ \(0\)\
\-\ sir\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ rubbery\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ depleted\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ np\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ surface\\:\\ 0\\.011660257517920406\ \(0\)\
\-\ potter\\:\\ 0\\.01148257196730542\ \(0\)\
\-\ ii\\:\\ 0\\.011392951187151236\ \(0\)\
\-\ inflammation\\:\\ 0\\.011232565297293395\ \(0\)\
\-\ cxr\\:\\ 0\\.011146931286321722\ \(0\)\
\-\ arches\\:\\ 0\\.0111376823980408\ \(0\)\
\-\ update\\:\\ 0\\.0111376823980408\ \(0\)\
\-\ by\\:\\ 0\\.010995911153360701\ \(0\)\
\-\ thomas\\:\\ 0\\.010855887101605012\ \(0\)\
\-\ are\\:\\ 0\\.01080253977616323\ \(0\)\
\-\ plural\\:\\ 0\\.010617632573278492\ \(0\)\
\-\ goes\\:\\ 0\\.010617632573278492\ \(0\)\
\-\ made\\:\\ 0\\.0105220166062178\ \(0\)\
\-\ \\,\\:\\ 0\\.010460203458936916\ \(0\)\
\-\ bm\\:\\ 0\\.010411247113271502\ \(0\)\
\-\ rate\\:\\ 0\\.010295893324500288\ \(0\)\
\-\ pleural\\:\\ 0\\.010257651309654702\ \(0\)\
\-\ eur\\:\\ 0\\.010229202235904603\ \(0\)\
\-\ malignancy\\:\\ 0\\.010207386948381811\ \(0\)\
\-\ lymphomas\\:\\ 0\\.010066357544006881\ \(0\)\
\-\ pruritis\\:\\ 0\\.010066357544006881\ \(0\)\
\-\ cellularity\\:\\ 0\\.010066357544006881\ \(0\)\
\-\ http\\:\\ 0\\.010002437706275968\ \(0\)\
\-\ management\\:\\ 0\\.009967639701563034\ \(0\)\
\-\ prevalent\\:\\ 0\\.009919046601496333\ \(0\)\
\-\ cervical\\:\\ 0\\.009598427841086951\ \(0\)\
\-\ vein\\:\\ 0\\.009557753700198198\ \(0\)\
\-\ 8mm\\:\\ 0\\.009546307719244574\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.009468147712954761\ \(0\)\
\-\ biopsy\\:\\ 0\\.009371540159619043\ \(0\)\
\-\ ends\\:\\ 0\\.009339922259237583\ \(0\)\
\-\ adolescents\\:\\ 0\\.009339922259237583\ \(0\)\
\-\ 2mm\\:\\ 0\\.009157877381870686\ \(0\)\
\-\ enlarged\\:\\ 0\\.009012739012006202\ \(0\)\
\-\ splenomegaly\\:\\ 0\\.008995032689972962\ \(0\)\
\-\ it\\:\\ 0\\.008906561288406568\ \(0\)\
\-\ widespread\\:\\ 0\\.008847721747462414\ \(0\)\
\-\ \\>\\:\\ 0\\.008776406536842548\ \(0\)\
\-\ constitutional\\:\\ 0\\.008713237393537175\ \(0\)\
\-\ is\\:\\ 0\\.008690738460351247\ \(0\)\
\-\ cancer\\:\\ 0\\.008683663877479954\ \(0\)\
\-\ yr\\:\\ 0\\.008650143120708342\ \(0\)\
\-\ worst\\:\\ 0\\.008650143120708342\ \(0\)\
\-\ marker\\:\\ 0\\.00858952378044052\ \(0\)\
\-\ empty\\:\\ 0\\.00858952378044052\ \(0\)\
\-\ describe\\:\\ 0\\.008531192516170277\ \(0\)\
\-\ predominant\\:\\ 0\\.008531192516170277\ \(0\)\
\-\ svc\\:\\ 0\\.008474982865210656\ \(0\)\
\-\ medial\\:\\ 0\\.008449148419134626\ \(0\)\
\-\ divided\\:\\ 0\\.008317668036292662\ \(0\)\
\-\ histological\\:\\ 0\\.008221036881762005\ \(0\)\
\-\ sides\\:\\ 0\\.008221036881762005\ \(0\)\
\-\ interface\\:\\ 0\\.008174896289567754\ \(0\)\
\-\ formed\\:\\ 0\\.008174896289567754\ \(0\)\
\-\ approximately\\:\\ 0\\.008172543513309375\ \(0\)\
\-\ tracheal\\:\\ 0\\.008130093295946035\ \(0\)\
\-\ clavicle\\:\\ 0\\.008002986498052724\ \(0\)\
\-\ stages\\:\\ 0\\.007923707835939044\ \(0\)\
\-\ treated\\:\\ 0\\.007906803202732177\ \(0\)\
\-\ among\\:\\ 0\\.007848297999510246\ \(0\)\
\-\ bronchus\\:\\ 0\\.007811929379092636\ \(0\)\
\-\ role\\:\\ 0\\.007811929379092636\ \(0\)\
\-\ c\\/o\\:\\ 0\\.007741662958572146\ \(0\)\
\-\ 5\\:\\ 0\\.007728471166751664\ \(0\)\
\-\ cutaneous\\:\\ 0\\.007674452584631283\ \(0\)\
\-\ staging\\:\\ 0\\.007610043471183727\ \(0\)\
\-\ med\\:\\ 0\\.007578818266674423\ \(0\)\
\-\ lymphoma\\:\\ 0\\.007549300260863943\ \(0\)\
\-\ sweats\\:\\ 0\\.0075181989264066\ \(0\)\
\-\ time\\:\\ 0\\.007460900238761399\ \(0\)\
\-\ 4\\:\\ 0\\.0073600368011717005\ \(0\)\
\-\ nearly\\:\\ 0\\.007271475362895188\ \(0\)\
\-\ one\\:\\ 0\\.007158365945318838\ \(0\)\
\-\ etc\\:\\ 0\\.007149712027728087\ \(0\)\
\-\ superficial\\:\\ 0\\.007058768441912115\ \(0\)\
\-\ trachea\\:\\ 0\\.007015227673802848\ \(0\)\
\-\ outer\\:\\ 0\\.007015227673802848\ \(0\)\
\-\ non\\-tender\\:\\ 0\\.00699390878333556\ \(0\)\
\-\ half\\:\\ 0\\.006972879954810399\ \(0\)\
\-\ 29\\:\\ 0\\.006891514060706192\ \(0\)\
\-\ late\\:\\ 0\\.006871824685470598\ \(0\)\
\-\ group\\:\\ 0\\.006871824685470598\ \(0\)\
\-\ mucosal\\:\\ 0\\.006814218202012743\ \(0\)\
\-\ adults\\:\\ 0\\.006740604525058717\ \(0\)\
\-\ types\\:\\ 0\\.006740604525058717\ \(0\)\
\-\ end\\:\\ 0\\.006705072039394577\ \(0\)\
\-\ painless\\:\\ 0\\.006636367615019255\ \(0\)\
\-\ more\\:\\ 0\\.006606418266807314\ \(0\)\
\-\ undergoing\\:\\ 0\\.006476886569833426\ \(0\)\
\-\ anteriorly\\:\\ 0\\.006476886569833426\ \(0\)\
\-\ complication\\:\\ 0\\.006476886569833426\ \(0\)\
\-\ night\\:\\ 0\\.006417433276436524\ \(0\)\
\-\ granulomatous\\:\\ 0\\.006374297591556962\ \(0\)\
\-\ pediatric\\:\\ 0\\.0063601824701299565\ \(0\)\
\-\ 70\\:\\ 0\\.006346195089109991\ \(0\)\
\-\ into\\:\\ 0\\.006285398355362308\ \(0\)\
\-\ 90\\:\\ 0\\.006225698116204718\ \(0\)\
\-\ iii\\:\\ 0\\.00620015050886127\ \(0\)\
\-\ or\\:\\ 0\\.006191794429451051\ \(0\)\
\-\ current\\:\\ 0\\.006187533336312334\ \(0\)\
\-\ recently\\:\\ 0\\.006162603843375885\ \(0\)\
\-\ involves\\:\\ 0\\.006138070073427986\ \(0\)\
\-\ 27\\:\\ 0\\.006125947697135828\ \(0\)\
\-\ 35\\:\\ 0\\.006078387173694169\ \(0\)\
\-\ subtle\\:\\ 0\\.006066722249991877\ \(0\)\
\-\ margins\\:\\ 0\\.005998523169761679\ \(0\)\
\-\ r\\:\\ 0\\.005998523169761679\ \(0\)\
\-\ can\\:\\ 0\\.005991413763428345\ \(0\)\
\-\ present\\:\\ 0\\.005966023968876911\ \(0\)\
\-\ pe\\:\\ 0\\.0059332066175362035\ \(0\)\
\-\ important\\:\\ 0\\.0059332066175362035\ \(0\)\
\-\ adenopathy\\:\\ 0\\.005880808546940096\ \(0\)\
\-\ mixed\\:\\ 0\\.005800499831436679\ \(0\)\
\-\ may\\:\\ 0\\.005793905313440878\ \(0\)\
\-\ under\\:\\ 0\\.005771428220992326\ \(0\)\
\-\ 60\\:\\ 0\\.005761857942402031\ \(0\)\
\-\ young\\:\\ 0\\.0057523465582067015\ \(0\)\
\-\ 5\\.\\:\\ 0\\.005696475593575618\ \(0\)\
\-\ but\\:\\ 0\\.005633704176301507\ \(0\)\
\-\ al\\:\\ 0\\.005599013250504309\ \(0\)\
\-\ characteristic\\:\\ 0\\.0055904503751169595\ \(0\)\
\-\ and\\/or\\:\\ 0\\.005581934678345754\ \(0\)\
\-\ best\\:\\ 0\\.00555666553151186\ \(0\)\
\-\ the\\:\\ 0\\.0055556126774254574\ \(0\)\
\-\ involved\\:\\ 0\\.0055400460697247475\ \(0\)\
\-\ around\\:\\ 0\\.00549926283143542\ \(0\)\
\-\ references\\:\\ 0\\.005491233748163234\ \(0\)\
\-\ an\\:\\ 0\\.005479126109511885\ \(0\)\
\-\ done\\:\\ 0\\.005475299637407653\ \(0\)\
\-\ i\\:\\ 0\\.005459528122455193\ \(0\)\
\-\ occurs\\:\\ 0\\.005420789376453313\ \(0\)\
\-\ et\\:\\ 0\\.005405561715799508\ \(0\)\
\-\ where\\:\\ 0\\.005390482620057059\ \(0\)\
\-\ 25\\:\\ 0\\.005338835020490066\ \(0\)\
\-\ enlargement\\:\\ 0\\.005240445759636932\ \(0\)\
\-\ use\\:\\ 0\\.005220153191720715\ \(0\)\
\-\ also\\:\\ 0\\.005207479424019015\ \(0\)\
\-\ classic\\:\\ 0\\.005060672146534887\ \(0\)\
\-\ 50\\:\\ 0\\.005024726455400007\ \(0\)\
\-\ effusion\\:\\ 0\\.005018815950858425\ \(0\)\
\-\ occur\\:\\ 0\\.004955249812645345\ \(0\)\
\-\ abnormality\\:\\ 0\\.004872577965735011\ \(0\)\
\-\ laboratory\\:\\ 0\\.004867220611830087\ \(0\)\
\-\ diagnosed\\:\\ 0\\.004856561293346222\ \(0\)\
\-\ congenital\\:\\ 0\\.004830230246742562\ \(0\)\
\-\ early\\:\\ 0\\.004830230246742562\ \(0\)\
\-\ iv\\:\\ 0\\.004819822159908955\ \(0\)\
\-\ malignant\\:\\ 0\\.0047738341211426595\ \(0\)\
\-\ otherwise\\:\\ 0\\.004743918444244737\ \(0\)\
\-\ weight\\:\\ 0\\.0047340738564773804\ \(0\)\
\-\ typically\\:\\ 0\\.004662172750395629\ \(0\)\
\-\ \\&\\:\\ 0\\.004638930281516896\ \(0\)\
\-\ involving\\:\\ 0\\.004634323437408491\ \(0\)\
\-\ was\\:\\ 0\\.004582430551222659\ \(0\)\
\-\ side\\:\\ 0\\.00457565147104184\ \(0\)\
\-\ benign\\:\\ 0\\.004558037661565999\ \(0\)\
\-\ neoplasm\\:\\ 0\\.0044979236103739224\ \(0\)\
\-\ thickening\\:\\ 0\\.004477008608490497\ \(0\)\
\-\ this\\:\\ 0\\.004456586769617309\ \(0\)\
\-\ 10\\:\\ 0\\.004452278560041593\ \(0\)\
\-\ type\\:\\ 0\\.004452278560041593\ \(0\)\
\-\ first\\:\\ 0\\.004431968214506726\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.0043960689090819715\ \(0\)\
\-\ unremarkable\\:\\ 0\\.004372591064423587\ \(0\)\
\-\ along\\:\\ 0\\.004364843704572668\ \(0\)\
\-\ x\\:\\ 0\\.004357134985081108\ \(0\)\
\-\ several\\:\\ 0\\.004245893100034602\ \(0\)\
\-\ right\\:\\ 0\\.004180672530651082\ \(0\)\
\-\ abscess\\:\\ 0\\.004175944735910768\ \(0\)\
\-\ any\\:\\ 0\\.004158941318504318\ \(0\)\
\-\ while\\:\\ 0\\.00415556296731424\ \(0\)\
\-\ age\\:\\ 0\\.004019954135308047\ \(0\)\
\-\ patient\\:\\ 0\\.00397183275540829\ \(0\)\
\-\ there\\:\\ 0\\.0039311145485780175\ \(0\)\
\-\ in\\:\\ 0\\.003907856848286754\ \(0\)\
\-\ neck\\:\\ 0\\.0038782737820996635\ \(0\)\
\-\ loss\\:\\ 0\\.003833793156829118\ \(0\)\
\-\ ct\\:\\ 0\\.003694910829650828\ \(0\)\
\-\ months\\:\\ 0\\.0036073281216229785\ \(0\)\
\-\ distal\\:\\ 0\\.0035908478963617104\ \(0\)\
\-\ at\\:\\ 0\\.0035788660056619258\ \(0\)\
\-\ significant\\:\\ 0\\.0035515411917375938\ \(0\)\
\-\ up\\:\\ 0\\.0035515411917375938\ \(0\)\
\-\ cm\\:\\ 0\\.0035424360399026055\ \(0\)\
\-\ mild\\:\\ 0\\.003477980608858017\ \(0\)\
\-\ common\\:\\ 0\\.0034563635424364717\ \(0\)\
\-\ for\\:\\ 0\\.0033807178453294363\ \(0\)\
\-\ both\\:\\ 0\\.0033727975126524286\ \(0\)\
\-\ to\\:\\ 0\\.003300371780857699\ \(0\)\
\-\ symptoms\\:\\ 0\\.0032915880632119615\ \(0\)\
\-\ tissue\\:\\ 0\\.0031304809713332206\ \(0\)\
\-\ imaging\\:\\ 0\\.003094395401013296\ \(0\)\
\-\ tumor\\:\\ 0\\.0030791843919796154\ \(0\)\
\-\ woman\\:\\ 0\\.003050854632904028\ \(0\)\
\-\ most\\:\\ 0\\.0030492042376013538\ \(0\)\
\-\ other\\:\\ 0\\.003044263599230987\ \(0\)\
\-\ diagnosis\\:\\ 0\\.00303279649270544\ \(0\)\
\-\ well\\:\\ 0\\.002987760360075195\ \(0\)\
\-\ of\\:\\ 0\\.002881083172747782\ \(0\)\
\-\ have\\:\\ 0\\.002860027941831672\ \(0\)\
\-\ 2\\:\\ 0\\.002844056408826192\ \(0\)\
\-\ presents\\:\\ 0\\.0026980591893476444\ \(0\)\
\-\ treatment\\:\\ 0\\.0026732874182393927\ \(0\)\
\-\ and\\:\\ 0\\.002503989260571818\ \(0\)\
\-\ on\\:\\ 0\\.002237684736832853\ \(0\)\
\-\ be\\:\\ 0\\.0020367182741019\ \(0\)\
\-\ mass\\:\\ 0\\.0018368794543239019\ \(0\)\
\-\ old\\:\\ 0\\.001352294585567627\ \(0\)\
\-\ a\\:\\ 0\\.0012259653842924304\ \(0\)\
\-\ \\.\\:\\ 0\\.001152226055709848\ \(0\)\
\-\ with\\:\\ 0\\.0009042053793654539\ \(0\)\
